Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?
CYP3A enzymes are involved in the metabolism of calcineurin inhibitor tacrolimus as well as vitamin D. In this review, we summarize the clinical aspects of CYP3A-mediated metabolism of tacrolimus and vitamin D with emphasis on the influence of single-nucleotide polymorphisms on tacrolimus disposition. We describe the utility of 4β hydroxycholesterol as a marker of CYP3A activity. Then, we discuss the possible interaction between calcineurin inhibitors and vitamin D in solid organ transplant recipients. Also, we review other mechanisms which may contribute to side effects of calcineurin inhibitors on bone. Lastly, suggestions for future research and clinical perspectives are discussed
|Keywords||Calcineurin inhibitors .CYP3A .CYP3A4 .CYP3A5 .Vitamin D . Mineral and bone disorder .Renal transplantation|
|Persistent URL||dx.doi.org/10.1007/s00467-018-4030-3, hdl.handle.net/1765/116796|
Prytula, A., Cransberg, K, & Raes, A. (2018). Drug-metabolizing enzymes CYP3A as a link between tacrolimus and vitamin D in renal transplant recipients: is it relevant in clinical practice?. Pediatric Nephrology, 34(7), 1201–1210. doi:10.1007/s00467-018-4030-3